Oncodesign Precision Medicine (FRA:ZR8) Other Financing: €0.00 Mil (TTM As of Dec. 2025)


FRA:ZR8 Oncodesign Precision Medicine SA FRA:ZR8
38 GF Score
Price €0.30
GF Value €0.26
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is Oncodesign Precision Medicine Other Financing?

Oncodesign Precision Medicine FRA:ZR8 38 Other Financing is €0.00 Mil as of Dec. 2025. GuruFocus rates FRA:ZR8 with a GF Score™ of 38/100 and a GF Value™ of €0.26 (Modestly Overvalued). The stock has 1 warning sign investors should review.

Oncodesign Precision Medicine's Other Financing for the six months ended in Dec. 2025 was €0.00 Mil.

Oncodesign Precision Medicine's Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 was €0.00 Mil.

Oncodesign Precision Medicine Other Financing Historical Data

* Premium members only.

The historical data trend for Oncodesign Precision Medicine's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncodesign Precision Medicine Other Financing Chart

Oncodesign Precision Medicine Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Oncodesign Precision Medicine Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:ZR8
38GF Score
Oncodesign Precision Medicine SA FRA:ZR8
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oncodesign Precision Medicine Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of €0.00 Mil mean?
Oncodesign Precision Medicine (FRA:ZR8) has a Other Financing of €0.00 Mil as of Dec. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Oncodesign Precision Medicine and its competitors.
Is Oncodesign Precision Medicine's Other Financing too high?
Oncodesign Precision Medicine's current Other Financing is €0.00 Mil. Overall, Oncodesign Precision Medicine has a GF Score™ of 38/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oncodesign Precision Medicine's Other Financing compare to VRTX and REGN?
Oncodesign Precision Medicine's Other Financing of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Oncodesign Precision Medicine and its competitors. Oncodesign Precision Medicine's current Other Financing is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncodesign Precision Medicine stock overvalued right now?
Based on GuruFocus' analysis, Oncodesign Precision Medicine (FRA:ZR8) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.26, compared to a current price of €0.30 — trading 16.9% above its estimated fair value. The current Other Financing is €0.00 Mil. Oncodesign Precision Medicine's overall GF Score™ is 38/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Oncodesign Precision Medicine (FRA:ZR8), the current Other Financing is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oncodesign Precision Medicine (FRA:ZR8) Overvalued in 2026?

Based on GuruFocus' analysis, Oncodesign Precision Medicine stock appears to be overvalued. The current stock price of €0.30 is trading 16.9% above its estimated GF Value™ of €0.26. GuruFocus considers Oncodesign Precision Medicine to be Modestly Overvalued.

Key valuation signals for FRA:ZR8:

  • Other Financing: €0.00 Mil
  • GF Value™: €0.26 vs. price of €0.30 (16.9% above fair value)
  • GF Score™: 38/100 with 1 warning sign

No single metric tells the full story. See the FRA:ZR8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oncodesign Precision Medicine Business Description

Other Exchanges ALOPM:France
Address 18 rue Jean Mazen, Dijon, FRA, 21000
Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.
38GF Score

Get the complete analysis for FRA:ZR8

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.30
Price
€0.26
GF Value